Impact of ELX/TEZ/IVA on Patients With Cystic Fibrosis (TRAJECTORY)
Updated: Jun 27
We have recently commenced a new study in conjunction with with Vertex Pharmaceuticals Incorporated and Cardiff and Vale University Health Board called TRAJECTORY with Dr Helen Barr as the site Principal Investigator at NUH.
A Longitudinal Study on the Impact of ELX/TEZ/IVA Treatment in Patients With Cystic Fibrosis in the Real World
Why is this study being done?
Observational studies are studies in which, as a rule, only data that is generated in the context of standard of care is recorded and evaluated. This means that your doctor uses the data from the patient's file to monitor the course of the disease and its treatment and document it for the purposes of the study.
The purpose of this observational study is to collect information on the clinical characteristics (e.g. details of any respiratory infections), assessments (laboratory and test results), treatment requirements (e.g. hospital visits, medications needed) and quality of life of Cystic Fibrosis patients treated with Kaftrio where it is prescribed by their doctor in routine clinical practice.
No part of this study is experimental. All data needed for the purpose of the study will be collected from information that is already documented in patient medical records for the duration of the study. The Patients doctor will continue to make all decisions regarding their proper treatment and care.
There will be approximately 600 Patients with cystic fibrosis participating in this multi country study.
Fore more information, please contact:
This study has completed recruitment